Cargando…

Enhanced expression of ten‐eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P‐glycoprotein expression

Increasing evidence revealed that ten‐eleven translocation 1 (TET1) plays an important role in tumorigenesis and chemoresistance, but its functions in gemcitabine resistance in cholangiocarcinoma (CCA) remain unknown. This study aims to investigate the effect of TET1 on gemcitabine resistance in CCA...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chuanxu, Ye, Hua, Zhang, Lei, Cheng, Yayu, Xu, Shifeng, Zhang, Ping, Zhang, Zijie, Bai, Jimin, Meng, Fangkang, Zhong, Lin, Shi, Guangjun, Li, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434196/
https://www.ncbi.nlm.nih.gov/pubmed/30784212
http://dx.doi.org/10.1002/cam4.1983
_version_ 1783406430353620992
author Wang, Chuanxu
Ye, Hua
Zhang, Lei
Cheng, Yayu
Xu, Shifeng
Zhang, Ping
Zhang, Zijie
Bai, Jimin
Meng, Fangkang
Zhong, Lin
Shi, Guangjun
Li, Hao
author_facet Wang, Chuanxu
Ye, Hua
Zhang, Lei
Cheng, Yayu
Xu, Shifeng
Zhang, Ping
Zhang, Zijie
Bai, Jimin
Meng, Fangkang
Zhong, Lin
Shi, Guangjun
Li, Hao
author_sort Wang, Chuanxu
collection PubMed
description Increasing evidence revealed that ten‐eleven translocation 1 (TET1) plays an important role in tumorigenesis and chemoresistance, but its functions in gemcitabine resistance in cholangiocarcinoma (CCA) remain unknown. This study aims to investigate the effect of TET1 on gemcitabine resistance in CCA and the possible effect on P‐glycoprotein (P‐gp) expression encoded by multidrug resistance (MDR) genes. We established two kinds of gemcitabine‐resistant CCA cell lines and confirmed its specific features. The expression of TET1 and P‐gp was evaluated in gemcitabine‐resistant CCA cells and their parental cells at mRNA and protein level by quantitative RT‐PCR and western blot analysis. After transfecting the gemcitabine‐resistant CCA cell lines with TET1 gene or siRNA, the cell viability test was obtained to verify the effect of TET1 on the sensitivity of CCA cells to gemcitabine. And then, the possible effect of TET1 on the expression of P‐gp was examined by western blot analysis. Xenograft tumor experiment was conducted to confirm the association between TET1 and P‐gp expression under gemcitabine chemoresistance. The associations between clinical outcomes of CCA patients with chemotherapy and TET1 expression were analyzed in 82 patients. The results showed that TET1 expression was significantly decreased, and P‐gp expression was increased in gemcitabine‐resistant CCA cells. Additionally, overexpression of TET1 augmented the sensitivity of CCA cells to gemcitabine and induced the decreased expression of P‐gp in gemcitabine‐resistant CCA cells. Furthermore, multivariate Cox regression analysis indicated that TET1 expression and TNM stage were independent risk factors (P < 0.001) for the clinical outcomes of CCA patients with chemotherapy. Additionally, Kaplan‐Meier survival and the log‐rank test showed that decreased expression of TET1 was associated with poorer prognosis of CCA patients with chemotherapy. These findings suggest that TET1 expression reverses gemcitabine resistance in CCA accompanied by a reduction in P‐gp expression. Thus, TET1 may be a promising target to overcome chemoresistance in CCA.
format Online
Article
Text
id pubmed-6434196
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-64341962019-04-08 Enhanced expression of ten‐eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P‐glycoprotein expression Wang, Chuanxu Ye, Hua Zhang, Lei Cheng, Yayu Xu, Shifeng Zhang, Ping Zhang, Zijie Bai, Jimin Meng, Fangkang Zhong, Lin Shi, Guangjun Li, Hao Cancer Med Clinical Cancer Research Increasing evidence revealed that ten‐eleven translocation 1 (TET1) plays an important role in tumorigenesis and chemoresistance, but its functions in gemcitabine resistance in cholangiocarcinoma (CCA) remain unknown. This study aims to investigate the effect of TET1 on gemcitabine resistance in CCA and the possible effect on P‐glycoprotein (P‐gp) expression encoded by multidrug resistance (MDR) genes. We established two kinds of gemcitabine‐resistant CCA cell lines and confirmed its specific features. The expression of TET1 and P‐gp was evaluated in gemcitabine‐resistant CCA cells and their parental cells at mRNA and protein level by quantitative RT‐PCR and western blot analysis. After transfecting the gemcitabine‐resistant CCA cell lines with TET1 gene or siRNA, the cell viability test was obtained to verify the effect of TET1 on the sensitivity of CCA cells to gemcitabine. And then, the possible effect of TET1 on the expression of P‐gp was examined by western blot analysis. Xenograft tumor experiment was conducted to confirm the association between TET1 and P‐gp expression under gemcitabine chemoresistance. The associations between clinical outcomes of CCA patients with chemotherapy and TET1 expression were analyzed in 82 patients. The results showed that TET1 expression was significantly decreased, and P‐gp expression was increased in gemcitabine‐resistant CCA cells. Additionally, overexpression of TET1 augmented the sensitivity of CCA cells to gemcitabine and induced the decreased expression of P‐gp in gemcitabine‐resistant CCA cells. Furthermore, multivariate Cox regression analysis indicated that TET1 expression and TNM stage were independent risk factors (P < 0.001) for the clinical outcomes of CCA patients with chemotherapy. Additionally, Kaplan‐Meier survival and the log‐rank test showed that decreased expression of TET1 was associated with poorer prognosis of CCA patients with chemotherapy. These findings suggest that TET1 expression reverses gemcitabine resistance in CCA accompanied by a reduction in P‐gp expression. Thus, TET1 may be a promising target to overcome chemoresistance in CCA. John Wiley and Sons Inc. 2019-02-19 /pmc/articles/PMC6434196/ /pubmed/30784212 http://dx.doi.org/10.1002/cam4.1983 Text en © 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Wang, Chuanxu
Ye, Hua
Zhang, Lei
Cheng, Yayu
Xu, Shifeng
Zhang, Ping
Zhang, Zijie
Bai, Jimin
Meng, Fangkang
Zhong, Lin
Shi, Guangjun
Li, Hao
Enhanced expression of ten‐eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P‐glycoprotein expression
title Enhanced expression of ten‐eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P‐glycoprotein expression
title_full Enhanced expression of ten‐eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P‐glycoprotein expression
title_fullStr Enhanced expression of ten‐eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P‐glycoprotein expression
title_full_unstemmed Enhanced expression of ten‐eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P‐glycoprotein expression
title_short Enhanced expression of ten‐eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P‐glycoprotein expression
title_sort enhanced expression of ten‐eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in p‐glycoprotein expression
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434196/
https://www.ncbi.nlm.nih.gov/pubmed/30784212
http://dx.doi.org/10.1002/cam4.1983
work_keys_str_mv AT wangchuanxu enhancedexpressionofteneleventranslocation1reversesgemcitabineresistanceincholangiocarcinomaaccompaniedbyareductioninpglycoproteinexpression
AT yehua enhancedexpressionofteneleventranslocation1reversesgemcitabineresistanceincholangiocarcinomaaccompaniedbyareductioninpglycoproteinexpression
AT zhanglei enhancedexpressionofteneleventranslocation1reversesgemcitabineresistanceincholangiocarcinomaaccompaniedbyareductioninpglycoproteinexpression
AT chengyayu enhancedexpressionofteneleventranslocation1reversesgemcitabineresistanceincholangiocarcinomaaccompaniedbyareductioninpglycoproteinexpression
AT xushifeng enhancedexpressionofteneleventranslocation1reversesgemcitabineresistanceincholangiocarcinomaaccompaniedbyareductioninpglycoproteinexpression
AT zhangping enhancedexpressionofteneleventranslocation1reversesgemcitabineresistanceincholangiocarcinomaaccompaniedbyareductioninpglycoproteinexpression
AT zhangzijie enhancedexpressionofteneleventranslocation1reversesgemcitabineresistanceincholangiocarcinomaaccompaniedbyareductioninpglycoproteinexpression
AT baijimin enhancedexpressionofteneleventranslocation1reversesgemcitabineresistanceincholangiocarcinomaaccompaniedbyareductioninpglycoproteinexpression
AT mengfangkang enhancedexpressionofteneleventranslocation1reversesgemcitabineresistanceincholangiocarcinomaaccompaniedbyareductioninpglycoproteinexpression
AT zhonglin enhancedexpressionofteneleventranslocation1reversesgemcitabineresistanceincholangiocarcinomaaccompaniedbyareductioninpglycoproteinexpression
AT shiguangjun enhancedexpressionofteneleventranslocation1reversesgemcitabineresistanceincholangiocarcinomaaccompaniedbyareductioninpglycoproteinexpression
AT lihao enhancedexpressionofteneleventranslocation1reversesgemcitabineresistanceincholangiocarcinomaaccompaniedbyareductioninpglycoproteinexpression